Form D · Biotechnology
Arch Biopartners Inc.
Toronto, A6 · CIK 0001600660
Offering snapshot reported Jan 22, 2015 · SEC filing
- Reported sold
- $265K Offering amount: $265K
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 12, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 22, 2015 | Initial | $265,000 | No comparison | 6 | SEC filing |
| Aug 18, 2014 | Initial | $155,519 | No comparison | 4 | SEC filing |
| Apr 4, 2014 | Initial | $140,000 | No comparison | 3 | SEC filing |
| Mar 6, 2014 | Initial | $70,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-232696
Source: Form D, filed Jan 22, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Claude Allary | Director |
| Andrew Bishop | Director, Executive |
| Conor Gunne | Director |
| Adrian Haigh | Director |
| Jerome Mc Elroy | Director |
| Daniel Muruve | Executive |
| Richard Muruve | Director, Executive |
| Richard Rossman | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
174 Spadina Avenue Suite 502 A
Toronto, A6, M5T 2C2
Toronto, A6, M5T 2C2